Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Moderate Buy” by Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $43.60.

A number of analysts have weighed in on COLL shares. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 26,067 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the completion of the sale, the executive vice president now directly owns 108,137 shares in the company, valued at approximately $3,081,904.50. The trade was a 19.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares of the company’s stock, valued at $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 95,516 shares of company stock worth $2,833,180 over the last three months. 3.98% of the stock is currently owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in COLL. Invesco Ltd. grew its position in Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock valued at $50,876,000 after buying an additional 289,335 shares during the period. Janus Henderson Group PLC grew its position in Collegium Pharmaceutical by 319.4% during the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company’s stock valued at $8,341,000 after buying an additional 221,903 shares during the period. Victory Capital Management Inc. grew its position in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after buying an additional 215,874 shares during the period. JPMorgan Chase & Co. grew its position in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after buying an additional 175,892 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Collegium Pharmaceutical during the fourth quarter valued at approximately $3,489,000.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $29.66 on Tuesday. The company has a market capitalization of $933.87 million, a price-to-earnings ratio of 12.78 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical has a one year low of $27.28 and a one year high of $42.29. The company’s 50-day moving average is $30.80 and its 200 day moving average is $33.15.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Sell-side analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.